What Happened

Ollin Biosciences will present Phase 1b JADE trial data for OLN324 at ASRS 2026 on July 16. The head-to-head study showed OLN324 achieved faster and greater anatomic outcomes than faricimab in both DME and wAMD, with numerically superior vision gains.

Who Is Affected

Retina specialists currently prescribing VEGF inhibitors (Genentech's Vabysmo, Regeneron's Eylea) for DME/wAMD. Innovent Biologics, Ollin's discovery partner, gains validation for its bispecific antibody platform.

Market Impact

• Potential share shift from $12B+ VEGF inhibitor market if Phase 3 confirms superiority
• Increased pressure on Genentech/Regeneron to defend franchise positioning
• New partnership opportunities for retinal drug delivery platforms

What to Watch

Phase 3 trial initiation in late 2026. Competitive response from incumbents. Further details on dosing frequency advantage - a key adoption driver in retinal therapeutics.